FiercePharma

Intercept's liver med Ocaliva takes heat at FDA expert meeting, as hopes for full approval dim

Following a meeting with the FDA’s Gastrointestinal Drug Advisory Committee Friday, the future of Intercept’s rare liver disease drug Ocaliva is under serious threat. Looking to assess whether Ocaliva ...
Nasdaq

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint

Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE study MORRISTOWN, N.J., Sept ...
Seeking Alpha

Intercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All Parties

Intercept Pharmaceuticals, the developer of liver disease drug Ocaliva, has agreed to be acquired by Italian Pharma company Alfasigma in an all-cash deal worth approximately $800 million. Intercept ...
Nasdaq

Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why

Shares of Intercept Pharmaceuticals, Inc. ICPT gained 12.4% in the last six months compared with the industry’s growth of 0.3%. Investors are upbeat on the performance of lead drug Ocaliva and the ...